Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026
Climb Bio (CLYM) and Mabworks presented Phase 1 data for CLYM116/MIL116 at ASN Kidney Week 2026, showing 90% free APRIL suppression and 70% Gd-IgA1 reduction. The drug has a 33-day half-life, supports Q12W dosing, and is generally well-tolerated. NAVIGATE-2 Phase 2 trial is enrolling, with initial data expected in 2027, and a global Phase 3 trial is planned for 2027.
How this was made
The 30-second read
Why it matters
The data suggest deep, durable target suppression and a favorable safety profile, supporting a Q12W dosing regimen and advancing the program toward Phase 2 and Phase 3 trials.
Market read
First‑time release of promising early‑stage data could move Climb Bio's share price and influence investor sentiment toward renal‑disease therapeutics.
What to watch
Regulatory feedback and the need for larger Phase 2/3 trials could delay commercialization, tempering short‑term upside.
Background
Climb Bio announced additional Phase 1 data for its anti‑APRIL monoclonal antibody CLYM116/MIL116, presented at ASN Kidney Week 2026.
Ticker impact
Climb Bio disclosed Phase 1 data showing >90% APRIL suppression and ~70% Gd-IgA1 reduction, a first‑time report of its anti‑APRIL antibody program.
likely upward pressure as market prices in the promising Phase 1 results
First disclosure of robust pharmacodynamic outcomes and long half‑life supports a strong development narrative, prompting buying interest.
Market effects
Strengthens the biotech sector's view on APRIL‑targeted therapies and may boost peer companies developing similar antibodies.
Highlights Chinese partnership but primary impact is on US‑listed Climb Bio.
Adds to the pipeline of novel kidney disease treatments, relevant for global investors tracking renal‑focused biotech.
Counterpoint
Phase 1 data, while encouraging, remains early; investors may wait for patient‑level efficacy before committing.
Key entities
- companyClimb Bio, Inc.
US‑listed biotech developing CLYM116/MIL116 for IgA nephropathy.
- companyBeijing Mabworks Biotech Co., Ltd.
Chinese partner conducting parallel Phase 1 studies.
